The Positives
The Negative
Outlook
High vaccination rates in ART’s eight key markets – France, UK, US, Australia, China, Japan, Singapore and Vietnam. As at end-Oct21, with exception of Vietnam, these countries have fully vaccinated between 68%-84% of its population. While fully vaccinated population in Vietnam is relatively low at 23%, vaccination rates in cities where ART has presence in such as Ho Chin Minh City and Hanoi have reached 60% and 80% respectively. UK, France and US have recovered ahead of the rest of ART’s territories, owing to domestic leisure demand. These countries are also one of the first to reopen leisure travel lanes with selected countries. Following the lifting of lockdown in Brisbane in Sep21, and Melbourne and Sydney and October in Oct21, Australia has lifted its international travel ban for citizens and will be added to Singapore’s VTL on 8 November 2021.
Three properties in Australia and two in Singapore have been block booked by the government until 1Q22. With international travel returning, ART will periodically review whether government business remains relevant or if the asset should be converted to take on leisure demand.
Picking up two more PBSAs in the US. Wildwood Lubbock was acquired on 21 September 2021 for S$94.8mn, at an entry yield of 5.1%. Located in Texas, the PBSA serves students attending Texas Tech University. It is fully booked for AY2021 (Sep21 to Aug22). Bed rates have increased 5% from the preceding academic year, AY2020. Acquisition of ART’s fourth PBSA asset, Seven07, is estimated to be completed in mid-November 2021. The S$112.4mn asset is located in Illinois and serves students attending the University of Illinois Urbana-Champaign. Entry yield of 4.5% is expected to increase to 4.8% on the back of 8% YoY growth in bed rates. Seven07 is fully leased for AY2021 and has secured bookings for 50% of beds for AY2022 in just two months after opening AY2022 for booking. Post-acquisition, this segment will account for 11% of AUM, up from 5% as at Dec20, bringing ART closer to its’ 15-20% medium-term target for the extended stay segment. Theses extended stay assets have maintained occupancies above 95% in 2020 and have long average lengths of stay of one year, providing ART with stable income.
Maintain ACCUMULATE and DDM-based TP of S$1.19
FY21 recovery has been more laboured that we initially anticipated. As such, we tweak our FY21e-25e DPU estimates between -5.8%-0.3%, with no impact to our DDM-derived TP of S$1.19. We have incorporated a more gradual pace of recovery as well as incorporating the two PBSA acquisitions, Wildwood Lubbock and Seven07.
With most of ART’s markets gradually opening up, ART is poised tap the recovery in domestic and international travel demand. Recent acquisitions in the extended stay segment, reopening of voco Times Square South post refurbishment in 4Q21 and opening of Lyf One-North in 4Q21 will aid DPU recovery.
ART remains our top pick in the sector owing to its mix of stable and growth revenue, geographical diversification and potentially faster recovery than peers from its exposure to markets with countries with large domestic tourism markets. Current share price implies FY21e/22e DPU yield of 4.1%/5.2%.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
